·
·
Wednesday, 30 September 2026dailybeirut.com
Health
A Japanese hospital performed the world's first commercial transplant of iPSC-derived heart muscle patches, marking a milestone after conditional government approval.
A surgeon announced that a Japanese medical facility has completed the world’s first procedure to transplant heart muscle tissue patches derived from stem cells using a commercially available therapy. The operation followed the receipt of conditional government authorization for the treatment.
The surgery took place on Tuesday at Osaka Katsutsu Hospital and lasted one hour. A woman in her fifties underwent the procedure, during which a medical team implanted patches of muscle cells into her heart. These cells were generated from induced pluripotent stem cells, commonly abbreviated as iPSCs.
This event marks the initial use of the therapy outside clinical trials since it secured conditional approval last March. Yoshiki Sawa, the hospital director and the surgeon who led the operation, told reporters afterward that they hope the treatment will improve the patient’s quality of life.
The therapy is primarily designed for heart patients who have exhausted other available treatment options. Its goals include enhancing heart muscle function, alleviating symptoms of heart failure, and increasing patients' tolerance for physical exertion.
Eight individuals suffering from ischemic heart disease, a condition caused by narrowed arteries supplying the heart, previously participated in clinical trials for this specific treatment. Japanese media reported that all eight patients experienced symptom improvement, with four showing enhanced cardiac function.
Sawa developed the technique in collaboration with Shinya Yamanaka, a Japanese scientist who received the Nobel Prize in 2012 for his research on induced pluripotent stem cells. These cells are produced by reprogramming specialized adult cells back to a state where they can transform into various body cell types without requiring embryos.
According to Japanese media reports, Sawa’s team plans to perform similar procedures for 75 patients by 2033. They intend to submit a report detailing the therapy's effectiveness. The Asahi Shimbun newspaper noted that final licensing for the treatment depends on proving its efficacy and safety over the next seven years.
